Gabinet Okulistyczny Jerzy Mackiewicz
- Address
- Ul. Polnocna 5/U9, 20-064 Lublin, Poland
Eye Diseases Research
The clinical trial activity at Gabinet Okulistyczny Jerzy Mackiewicz focuses on ophthalmology, with studies centered on serious retinal diseases that can threaten vision. The main goal is to assess whether newer treatment approaches can improve vision outcomes and better control disease activity in conditions affecting the macula and retina.
- Neovascular age-related macular degeneration and wet AMD
- Diabetic macular edema and vision-related complications of diabetes
- Choroidal neovascularization secondary to pathologic myopia
Overall, the research is aimed at comparing emerging eye treatments with established therapies to determine which options may offer better visual improvement and disease control for patients.
Retinal Treatment Studies
This site is also involved in trials exploring advanced retinal therapy for people with chronic macular disorders. These studies are designed to evaluate treatment effectiveness, with a strong emphasis on preserving or improving best corrected visual acuity while addressing ongoing retinal damage.
- Comparing new therapies with aflibercept
- Assessing options for wet age-related macular degeneration
- Studying treatment responses in diabetic eye disease
The research reflects a practical effort to identify therapies that may provide longer-lasting or more effective control of retinal vascular disease.
Innovative Ophthalmic Therapies
Clinical research at this health care site in Lublin includes evaluation of novel intravitreal treatments for conditions where abnormal blood vessel growth and fluid leakage damage central vision. The studies are intended to test whether these approaches can offer meaningful benefits compared with current standard care.
- Evaluating combination therapy for neovascular AMD
- Testing sustained delivery approaches for macular edema
- Comparing newer agents with established anti-VEGF treatments
In this setting, the focus remains on improving real-world outcomes for patients with retinal and macular disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Eyepoint Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eyepoint Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gabinet Okulistyczny Jerzy Mackiewicz
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 to Aflibercept in Participants with Diabetic Macular Edema | Eyepoint Inc. | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 3 | Unknown | 2021-08-27 | 2026-05-06 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.